Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Doxercalciferol (TSA 840) 是一种维生素 D2 类似物,是一种维生素 D 受体激活剂,能够阻碍肾病的进程。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 369 | 现货 | ||
2 mg | ¥ 531 | 现货 | ||
5 mg | ¥ 913 | 现货 | ||
10 mg | ¥ 1,530 | 现货 | ||
25 mg | ¥ 3,180 | 现货 | ||
50 mg | ¥ 4,720 | 现货 | ||
100 mg | ¥ 6,720 | 现货 | ||
500 mg | ¥ 13,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 917 | 现货 |
产品描述 | Doxercalciferol (TSA 840) is a synthetic vitamin D2 analog, suppressing parathyroid synthesis and secretion, used to treat secondary hyperparathyroidism and metabolic bone disease. |
体内活性 | Doxercalciferol (100 or 300 pg/g b.w.) normalizes serum calcium and parathyroid hormone (PTH) levels in nephrectomy treated mice. Doxercalciferol (300 pg/g b.w.) significantly reduces osteitis fibrosa in nephrectomy treated mice. [1] Doxercalciferol results in significant decrease in cardiac hypertrophy and improves cardiac function in rats fed a high salt (HS) diet. Doxercalciferol treatment leads to a significant decrease in plasma brain natriuretic peptide (BNP) level and tissue atrial natriuretic factor (ANF) mRNA level in rats fed a high salt (HS) diet. Doxercalciferol also significantly reduces the level of protein kinase C-α (PKCα) suggesting that PKC-mediated cardiac hypertrophy may be associated with vitamin D deficiency. [2] Doxercalciferol decreases proteinuria, podocyte injury, mesangial expansion, and extracellular matrix protein accumulation in Diet-induced obesity (DIO) mice. Doxercalciferol also decreases macrophage infiltration, oxidative stress, proinflammatory cytokines, and profibrotic growth factors in DIO mice. Doxercalciferol also prevents the activation of the renin-angiotensin-aldosterone system including the angiotensin II type 1 receptor and the mineralocorticoid receptor in DIO mice. [3] Doxercalciferol combined with Losartan most effectively prevents albuminuria, restored glomerular filtration barrier structure, and dramatically reduces glomerulosclerosis in a dose-dependent manner in mice. Doxercalciferol combined with Losartan virtually prevents morphological and molecular changes in diabetic kidneys of mice. [4] |
别名 | TSA 840, 度骨化醇, Hectorol, 1.alpha.-Hydroxyvitamin D2, 1α-hydroxyvitamin D2 |
分子量 | 412.65 |
分子式 | C28H44O2 |
CAS No. | 54573-75-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 20.6 mg/mL (50 mM)
DMSO: 4.1 mg/mL (10 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.4234 mL | 12.1168 mL | 24.2336 mL | 60.584 mL |
5 mM | 0.4847 mL | 2.4234 mL | 4.8467 mL | 12.1168 mL | |
10 mM | 0.2423 mL | 1.2117 mL | 2.4234 mL | 6.0584 mL | |
Ethanol | 20 mM | 0.1212 mL | 0.6058 mL | 1.2117 mL | 3.0292 mL |
50 mM | 0.0485 mL | 0.2423 mL | 0.4847 mL | 1.2117 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Doxercalciferol 54573-75-0 Others TSA840 1a-hydroxyvitamin D2 Vitamin D receptor 1alpha-hydroxyvitamin D2 inhibit TSA 840 Inhibitor 度骨化醇 Hectorol Vitamin D TSA-840 1.alpha.-Hydroxyvitamin D2 VD/VDR 1α-hydroxyvitamin D2 inhibitor